The use of a neonatal mouse model to study respiratory syncytial virus infections

Stephania Cormier, Dahui You, Srinivasa Honnegowda

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) infection is the most significant cause of viral death in infants worldwide. The significant morbidity and mortality associated with this disease underscores the urgent need for the development of an RSV vaccine. The development of an RSV vaccine has been hampered by our limited understanding of the human host immune system, which plays a significant role in RSV pathogenesis, susceptibility and vaccine efficacy. As a result, animal models have been developed to better understand the mechanisms by which RSV causes disease. Within the past few years, a revolutionary variation on these animal models has emerged - age at time of initial infection - and early studies in neonatal mice (aged <7 days at time of initial infection) indicate the validity of this model to understand RSV infection in infants. This article reviews available information on current murine and emerging neonatal mouse RSV models.

Original languageEnglish (US)
Pages (from-to)1371-1380
Number of pages10
JournalExpert Review of Anti-Infective Therapy
Volume8
Issue number12
DOIs
StatePublished - Dec 1 2010

Fingerprint

Respiratory Syncytial Virus Infections
Respiratory Syncytial Viruses
Respiratory Syncytial Virus Vaccines
Animal Models
Virus Diseases
Infection
Cause of Death
Immune System
Vaccines
Morbidity
Mortality

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

The use of a neonatal mouse model to study respiratory syncytial virus infections. / Cormier, Stephania; You, Dahui; Honnegowda, Srinivasa.

In: Expert Review of Anti-Infective Therapy, Vol. 8, No. 12, 01.12.2010, p. 1371-1380.

Research output: Contribution to journalReview article

Cormier, Stephania ; You, Dahui ; Honnegowda, Srinivasa. / The use of a neonatal mouse model to study respiratory syncytial virus infections. In: Expert Review of Anti-Infective Therapy. 2010 ; Vol. 8, No. 12. pp. 1371-1380.
@article{6cb6b6dfb973485ab725bfd76e3e1fcb,
title = "The use of a neonatal mouse model to study respiratory syncytial virus infections",
abstract = "Respiratory syncytial virus (RSV) infection is the most significant cause of viral death in infants worldwide. The significant morbidity and mortality associated with this disease underscores the urgent need for the development of an RSV vaccine. The development of an RSV vaccine has been hampered by our limited understanding of the human host immune system, which plays a significant role in RSV pathogenesis, susceptibility and vaccine efficacy. As a result, animal models have been developed to better understand the mechanisms by which RSV causes disease. Within the past few years, a revolutionary variation on these animal models has emerged - age at time of initial infection - and early studies in neonatal mice (aged <7 days at time of initial infection) indicate the validity of this model to understand RSV infection in infants. This article reviews available information on current murine and emerging neonatal mouse RSV models.",
author = "Stephania Cormier and Dahui You and Srinivasa Honnegowda",
year = "2010",
month = "12",
day = "1",
doi = "10.1586/eri.10.125",
language = "English (US)",
volume = "8",
pages = "1371--1380",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - The use of a neonatal mouse model to study respiratory syncytial virus infections

AU - Cormier, Stephania

AU - You, Dahui

AU - Honnegowda, Srinivasa

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Respiratory syncytial virus (RSV) infection is the most significant cause of viral death in infants worldwide. The significant morbidity and mortality associated with this disease underscores the urgent need for the development of an RSV vaccine. The development of an RSV vaccine has been hampered by our limited understanding of the human host immune system, which plays a significant role in RSV pathogenesis, susceptibility and vaccine efficacy. As a result, animal models have been developed to better understand the mechanisms by which RSV causes disease. Within the past few years, a revolutionary variation on these animal models has emerged - age at time of initial infection - and early studies in neonatal mice (aged <7 days at time of initial infection) indicate the validity of this model to understand RSV infection in infants. This article reviews available information on current murine and emerging neonatal mouse RSV models.

AB - Respiratory syncytial virus (RSV) infection is the most significant cause of viral death in infants worldwide. The significant morbidity and mortality associated with this disease underscores the urgent need for the development of an RSV vaccine. The development of an RSV vaccine has been hampered by our limited understanding of the human host immune system, which plays a significant role in RSV pathogenesis, susceptibility and vaccine efficacy. As a result, animal models have been developed to better understand the mechanisms by which RSV causes disease. Within the past few years, a revolutionary variation on these animal models has emerged - age at time of initial infection - and early studies in neonatal mice (aged <7 days at time of initial infection) indicate the validity of this model to understand RSV infection in infants. This article reviews available information on current murine and emerging neonatal mouse RSV models.

UR - http://www.scopus.com/inward/record.url?scp=78650207448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650207448&partnerID=8YFLogxK

U2 - 10.1586/eri.10.125

DO - 10.1586/eri.10.125

M3 - Review article

C2 - 21133663

AN - SCOPUS:78650207448

VL - 8

SP - 1371

EP - 1380

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 12

ER -